These inhibitors achieve their therapeutic effects by disrupting FAK-associated signaling pathways, including Src, AKT, and PI3K/AKT/mTOR, reducing cancer cell proliferation and increasing apoptosis. The gene discussed is AKT1; the disease is cancer.